Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Alpha Cognition Inc.

Get SEC filing alerts via email and in your feed for Alpha Cognition Inc.

ACOGF ACOG

Alpha Cognition Inc.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily Alzheimer's. Its key product, ZUNVEYL, is a next-generation acetylcholinesterase inhibitor approved for mild to moderate dementia. The company also advances pre-clinical programs targeting cognitive impairment, traumatic brain injury, and other neurodegenerative conditions, leveraging innovative formulations and strong intellectual property to address unmet medical needs in aging populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Alpha Cognition Inc.

1
1
Alpha Cognition Inc. Alpha Cognition Inc. Reports 21% Revenue Growth to $3.53 Million in Q1 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Alpha Cognition Inc. Alpha Cognition Inc. Reports $10.2 Million Revenue for Fiscal Year 2025, Highlights ZUNVEYL Launch

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Alpha Cognition Inc. Alpha Cognition Inc. Reports Significant Revenue Growth and Increased Operating Expenses for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Alpha Cognition Inc. Alpha Cognition Inc. Reports $1.66 Million Revenue in Q2 2025, Despite Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Alpha Cognition Inc. Alpha Cognition Inc. Reports $2.93 Million Revenue in Q1 2025, Net Loss Improves by 60%

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Alpha Cognition Inc. Alpha Cognition Inc. Reports $14.6 Million Net Loss for 2024, Launches ZUNVEYL for Alzheimer's Treatment

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Alpha Cognition Inc. Alpha Cognition Reports Financial Developments, Sees Increase in Cash and Cash Equivalents

Via official filing (AI summary) | over 1 year ago | 0 comments